Thaís S. Sabedot
A5004697744- Glioma Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Pituitary Gland Disorders and Treatments
- Ferroptosis and cancer prognosis
- Cancer Genomics and Diagnostics
- MicroRNA in disease regulation
- Radiomics and Machine Learning in Medical Imaging
- RNA modifications and cancer
- Cancer-related molecular mechanisms research
- Chromatin Remodeling and Cancer
- Histone Deacetylase Inhibitors Research
- Meningioma and schwannoma management
- Bioinformatics and Genomic Networks
- Single-cell and spatial transcriptomics
- Sirtuins and Resveratrol in Medicine
- Genomics and Chromatin Dynamics
- Genetic Syndromes and Imprinting
- Gene expression and cancer classification
- Gene Regulatory Network Analysis
- Circular RNAs in diseases
- Cancer Cells and Metastasis
- Diet and metabolism studies
- Adrenal and Paraganglionic Tumors
- Neuroendocrine Tumor Research Advances
- Neurofibromatosis and Schwannoma Cases
Henry Ford Health System
2017-2025
Michigan United
2019-2025
Henry Ford Hospital
2017-2023
Universidade de São Paulo
2015-2019
Clinics Hospital of Ribeirão Preto
2015
The Cancer Genome Atlas (TCGA) research network has made public a large collection of clinical and molecular phenotypes more than 10 000 tumor patients across 33 different types. Using this cohort, TCGA published over 20 marker papers detailing the genomic epigenomic alterations associated with these Although many important discoveries have been by TCGA's network, opportunities still exist to implement novel methods, thereby elucidating new biological pathways diagnostic markers. However,...
Glioma diagnosis is based on histomorphology and grading; however, such classification does not have predictive clinical outcome after glioblastomas developed. To date, no bona fide biomarkers that significantly translate into a survival benefit to glioblastoma patients been identified. We previously reported the IDH mutant G-CIMP-high subtype would be predecessor G-CIMP-low subtype. Here, we performed comprehensive DNA methylation longitudinal analysis of diffuse gliomas from 77 (200...
The detection of somatic mutations in cell-free DNA (cfDNA) from liquid biopsy has emerged as a noninvasive tool to monitor the follow-up cancer patients. However, significance cfDNA clinical utility remains uncertain patients with brain tumors, primarily because limited sensitivity detect real tumor-specific mutations. This unresolved challenge prevented accurate glioma approaches.Genome-wide methylation profiling tumor tissue and serum patients.Here, we developed approach profile status...
The CaCTS algorithm nominates cancer cell master transcription factors and guides a model of ovarian regulatory circuitry.
Abstract Recurrence of meningiomas is unpredictable by current invasive methods based on surgically removed specimens. Identification patients likely to recur using noninvasive approaches could inform treatment strategy, whether intervention or monitoring. In this study, we analyze the DNA methylation levels in blood (serum and plasma) tissue samples from 155 meningioma patients, compared other central nervous system tumor non-tumor entities. We discover markers unique use artificial...
Abstract Tumor adaptation or selection is thought to underlie therapy resistance in glioma. To investigate longitudinal epigenetic evolution of gliomas response therapeutic pressure, we performed an epigenomic analysis 132 matched initial and recurrent tumors from patients with IDH-wildtype (IDHwt) IDH-mutant (IDHmut) IDHwt showed a stable epigenome over time relatively low levels global methylation. The IDHmut high genome-wide DNA methylation that was progressively reduced similar those...
Survival in patients with IDH1/2-mutant (mt) anaplastic astrocytomas is highly variable. We have used the prospective phase 3 CATNON trial to identify molecular factors related outcome IDH1/2mt astrocytoma patients.The randomized 751 adult newly diagnosed 1p/19q non-codeleted glioma 59.4 Gy radiotherapy +/- concurrent and/or adjuvant temozolomide. The presence of necrosis microvascular proliferation was scored at central pathology review. Infinium MethylationEPIC BeadChip arrays were for...
Glioblastoma (GBM) tumors exhibit extensive genomic, epigenomic, and transcriptional diversity, with significant intratumoral heterogeneity, complicating standard treatment approaches involving radiation (RT) the DNA-alkylating agent temozolomide (TMZ). In this study, we employed an integrative multi-omics approach, including targeted proteomics, transcriptomics, genomics, DNA methylation profiling, to investigate response of a representative panel GBM patient-derived cancer stem cells...
Abstract Background Early detection of increased aggressiveness brain tumors is a major challenge in the field neuro-oncology because inability traditional imaging to uncover it. Isocitrate dehydrogenase (IDH)-mutant gliomas represent an ideal model system study molecular mechanisms associated with tumorigenicity they appear indolent and non-glycolytic initially, but eventually subset progresses toward secondary glioblastoma Warburg-like phenotype. The features this transformation are poorly...
We propose a generic framework for gene regulatory network (GRN) inference approached as feature selection problem. GRNs obtained using Machine Learning techniques are often dense, whereas real rather sparse. use Tikonov regularization inspired optimal L-curve criterion that utilizes the edge weight distribution given target to determine set of TFs associated with it. Our proposed allows incorporate mechanistic active biding based on cis-regulatory motif analysis. evaluate our in conjunction...
Abstract Background DNA methylation abnormalities are pervasive in pituitary neuroendocrine tumors (PitNETs). The feasibility to detect methylome alterations circulating cell-free (cfDNA) has been reported for several central nervous system (CNS) but not across PitNETs. aim of the study was use liquid biopsy (LB) approach PitNET-specific signatures differentiate these from other sellar diseases. Methods We profiled cfDNA (EPIC array) 59 serum and 41 plasma LB specimens patients with PitNETs...
// Fabiana M. Meliso 1, * , Danilo Micali Camila T. Silva 1 Thaís S. Sabedot 2 Simon G. Coetzee Adrian Koch 3 Fabian B. Fahlbusch 4 Houtan Noushmehr Regine Schneider-Stock and Miriam Jasiulionis Ontogeny Epigenetics Laboratory, Pharmacology Department, Universidade Federal de São Paulo - UNIFESP, Paulo, SP, Brazil Department of Genetics, Ribeirão Preto Medical School, University Preto, Experimental Tumorpathology, Institute Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU),...
Abstract Background Distinct genome-wide methylation patterns cluster pituitary neuroendocrine tumors (PitNETs) into molecular groups associated with specific clinicopathological features. Here we aim to identify, characterize, and validate signatures that objectively classify PitNET groups. Methods Combining in-house publicly available data, conducted an analysis of the methylome profile a comprehensive cohort 177 (Panpit cohort) 20 nontumor specimens from gland. We also retrieved data...
Summary To interrogate the factors driving therapy resistance in diffuse glioma, we collected and analyzed RNA and/or DNA sequencing data from temporally separated tumor pairs of 292 adult patients with IDH-wild-type or IDH-mutant glioma. Tumors recurred distinct manners that were dependent on IDH mutation status attributable to changes histological feature composition, somatic alterations, microenvironment interactions. Hypermutation acquired CDKN2A deletions associated an increase...
The function of critical developmental regulators can be subverted by cancer cells to control expression oncogenic transcriptional programs. These "master transcription factors" (MTFs) are often essential for cell survival and represent vulnerabilities that exploited therapeutically. current approaches identify candidate MTFs examine super-enhancer associated factor-encoding genes with high connectivity in network models. This relies on chromatin immunoprecipitation-sequencing (ChIP-seq)...
Gliomas are a heterogeneous group of brain tumors with distinct biological and clinical properties. Despite advances in surgical techniques regimens, treatment high-grade glioma remains challenging carries dismal rates therapeutic success overall survival. Challenges include the molecular complexity gliomas, as well inconsistencies histopathological grading, resulting an inaccurate prediction disease progression failure use standard therapy. The updated 2016 World Health Organization (WHO)...
SUMMARY Histomorphology and current grading schemes are unable to predict glioma relapse malignant tumor progression. We reported that the IDH-mutant associated Glioma-CpG Island Methylator Phenotype (G-CIMP) can be further divided into two clinically distinct subtypes independent of histopathological (G-CIMP-high -low) with evidence correlation Here we performed a comprehensive epigenomic analysis 74 longitudinally collected samples (grade II-IV) understand recurrence from G-CIMP-high...
Abstract The transcription factors (TF) which regulate gene expressions are key determinants of cellular phenotypes. Reconstructing large-scale genome-wide networks capture the influence TFs on target genes essential for understanding and accurate modelling living cells. We propose RGBM: a regulatory network (GRN) inference algorithm, can handle data from heterogeneous information sources including dynamic time-series, knockout, knockdown, DNA microarrays RNA-Seq expression profiles. RGBM...
<p>Supp Figures</p>
<p>Table S3A/B/C/D: Clinical summary of GLASS epigenomic samples S3A: IDHmut patients who switched from GCIMP-high to GCIMP-low S3B: and IDHwt with known hypermutator status S3C: treatment information S3D: information</p>